MS neurologist Pavle Repovic talks about TRANSFORMS trial in Neurology Today

September 18, 2015 Swedish Blogger

A post-hoc analysis of follow-up data from the TRANSFORMS trial suggests that early disease activity during a patient’s first year on fingolimod predicts longer-term outcomes in multiple sclerosis. Click here to read the analysis by Pavle Repovic, a neurologist at the Swedish Multiple Sclerosis Center.

Previous Article
Why we're "walking now" for Autism Speaks
Why we're "walking now" for Autism Speaks

A team from the Pediatric Neuroscience Center will proudly represent Swedish at Walk Now for Autism Speaks,...

Next Article
"Life goes on" despite multiple sclerosis

Ed. Note: This blog post was written by Ed Johnson about his experiences before and after being diagnosed w...